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Abstract 
Cognitive impairment affects 20-50% of HIV-1-infected (HIV+) adults on antiretroviral therapy (ART), 
and the search for protective factors has intensified as the population ages [1, 2]. Predictors of cognitive 
impairment in HIV+ populations are unknown, and multiple factors including ongoing low levels of viral 
replication, systemic inflammation, coinfection with Hepatitis C, genetic predisposition, irreversible CNS 
injury prior to ART, and neurotoxicity of ART regimens are potential candidates for influencing cognitive 
outcomes [3-5].  Furthermore, aging modifies inflammatory responses through molecular mechanisms 
that include altered lipid metabolism, mitochondrial function, and oxidative stress, coined 
“inflammaging” [6, 7]. The factors associated with HIV-associated neurocognitive impairment has been 
largely sought in cohort studies with cross-sectional designs, but these studies are limited by demographic 
differences that can influence neuropsychological test results, and difficulty in making associations 
between outcomes and exposures of long duration [4, 8-11].   To date, longitudinal studies investigating 
similar or overlapping age- and HIV-related mechanisms contributing to cognitive decline in older ART-
suppressed HIV+ adults are lacking.   
In the first portion of this thesis, we describe studies using a mixed-effects approach to model 
age-related cognitive trajectories of ART-adherent HIV+ and HIV- adults modified by time-varying lipid 
indices and APOE ε4 genotype.  This was a prospective study of HIV+ and HIV- men enrolled in the 
Multicenter AIDS Cohort Study from 1996-2010, and we showed that dyslipidemia and APOE ε4 allele are 
independent risk factors for cognitive decline in ART-adherent HIV+ men between ages 50-65.  The 
findings are significant because they identify novel risk factors for midlife cognitive decline in HIV+ men 
on suppressive ART and suggest that clinical management of dyslipidemia may be an effective strategy to 
reduce cognitive decline in HIV+ men over age 50.  Systemic inflammation, cardiovascular disease (CVD) 
and APOE ε4 genotype are associated with age-related cognitive decline in the general population [12-16], 
but the combined extent to which they account for midlife cognitive decline in HIV-infection remains 
unknown.   In the second portion of this thesis, we discuss our strategy to quantify the extent to which 
cognitive decline is explained by inflammation, CVD, and APOE ε4 genotype in older ART-adherent HIV-
adults, and determine how these variables influence the transition point from normal aging to cognitive 
decline in older ART-suppressed HIV+ individuals. 
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Introduction  
The population of HIV-1-infected (HIV+) individuals over age 50 is growing due to effective antiretroviral 
therapies (ART), and focus has shifted to prevention and management of age-related comorbidities. 
Dyslipidemia is common among people living with HIV infection (PLWH) in the current ART era. 
Persistent elevations in triglycerides and total cholesterol, and reductions in high-density lipoprotein 
(HDL) levels are detected in HIV+ cohorts, while elevations in low-density lipoprotein (LDL) are less 
consistent [17, 18]. Previous studies suggest that elevated total cholesterol or low HDL levels are 
associated with increased risk of late onset dementia in the general population [19, 20].   Furthermore, 
high total cholesterol was implicated as a risk factor for lower cognitive scores in PLWH and worsening 
HIV-1 associated neurocognitive disorders (HAND) [21], but the longitudinal effects of lipid levels on 
cognitive decline in ART-treated older HIV+ individuals are unknown. 
The main cholesterol transporter in the central nervous system is Apolipoprotein E (APOE), a structural 
component of very low density lipoproteins and HDL involved in catabolism of triglyceride-rich 
lipoproteins [22]. Three major APOE isoforms are encoded by the ε2, ε3, and ε4 alleles, with worldwide 
frequencies of ~8%, 78%, and 14%, respectively [23].  The ε4 allele is the most important genetic risk 
factor for Alzheimer’s disease (AD), and is a risk factor for age-related cognitive decline in the general 
population [12].  The relationship between APOE genotype and HAND is unclear due to conflicting results 
[3, 4, 9-11, 24-32].  While some cross-sectional studies suggest that the ε4 allele increases risk for HAND 
over age 50 [27, 31], others found no significant cognitive effect of the ε4 allele in HIV+ adults [3, 24, 26, 
28, 32]. The ε4 allele has been associated with hypercholesterolemia, but no studies have examined 
whether ε4 genotype interacts with cholesterol levels to influence cognitive decline in aging PLWH.  
It is critical to understand when lipids and APOE ε4 status modify cognitive performance among ART-
treated HIV+ adults, since these factors can guide clinical practice and trial design.  Here, we performed 
longitudinal growth modeling on a cohort of ART-adherent HIV+ and HIV- men between the ages 50-65 
years using a mixed-effects model approach to estimate the impact of lipid profiles and APOE ε4 allele on 
midlife cognitive trajectories.  We then examined whether cholesterol levels and ε4 genotype interact to 
influence risk of midlife cognitive decline. 
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Methods  
Data Source 
This was a prospective study using data from the Multicenter AIDS Cohort Study (MACS), an 
observational cohort of HIV+ and HIV- men who have sex with men.  Interviews, physical examinations, 
and biological specimens were collected in biannual visits; neuropsychological (NP) examinations began 
in 1986. Details of the study design and enrollment patterns have been previously described ([33], 
Supplementary Methods).  The Institutional Review Boards at each of the clinical sites approved the 
research, and subjects signed a written statement of informed consent.  The MACS public data is released 
annually (http://www.ntis.gov/search/index.aspx) [33]; the p23 release was translated to a local SQL 
database and used in these analyses.  
 
Study Population 
This study was restricted to MACS visits between January 1996 and December 2010.  A sequential process 
was performed to define the study cohort of 789 men between ages 50-65 (Figure 1; Supplementary Data). 
Among 3346 men with visits from 1996-2010, 1250 were outside the age for eligibility, had a history of 
CNS opportunistic infections, or reported cocaine, crack, or heroin use at >50% of visits during the study 
period while 653 were excluded due to ART adherence < 95% in follow-up, missing data, and other 
exclusion criteria (Fig. 1; Supplementary Methods). For inclusion, HIV+ participants had to be on ART for 
at least 1 year prior to baseline visit and have plasma viral load (VL) < 400 copies/ml at baseline visit.  
HIV- controls were matched to HIV+ cases with the MatchIt package in R (Version 2.4-21; 
http://gking.harvard.edu/matchit) [34].  Matched covariates included age at study entry, black race, 
education level, alcohol use, and smoking. 
 
Measures of cognitive function 
A battery of 15 NP tests measuring cognitive domains related to HAND was used to generate a composite 
cognitive summary score [35].  Individual tests were converted to z-scores using the test’s mean and 
standard deviation (SD) from HIV- and HCV-antibody negative men ages 45-49 years old stratified by 
education level as reference norms.  The summary cognitive score created to capture heterogeneity in 
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performance included: 1) executive function (trail-making part B, Stroop interference); 2) perceptual 
speed (Symbol Digit Modalities Test, Stroop color naming and word naming, trail-making part A); 3) 
attention and working memory (CalCAP reaction time measures); 4) verbal learning and memory (Rey 
Auditory Verbal Learning test (RAVLT) sum of trials 1-5; RAVLT immediate recall; RAVLT delayed 
recall); 5) motor (Grooved Pegboard, both scores) (Supplementary Table 1).   The following covariates 
with potential for confounding given published associations with HIV infection or cognitive function were 
used in adjusted models: baseline age (years), Shipley WAIS IQ-Equivalent score (IQ), Centers for 
Epidemiologic Studies Depression (CES-D) score, smoking, and CD4 cell count. 
 
Genotyping  
Genomic DNA extraction and genotyping of APOE single nucleotide polymorphisms (SNPs) rs429358 
[C/T] and rs7412 [C/T] from individuals within the MACS has been described [32].  Genotyping was 
conducted using TaqMan OpenArray technology. Arrays were imaged after amplification on OpenArray 
NT images, genotypes ascribed after clustering VIC and FAM signals (STATA 12.1, College Station, TX) 
and used to determine APOE alleles.  APOE genotype was available for 350 participants.  
 
Statistical Methods  
Cohort characteristics were described using means and SDs or median and interquartile range (IQR) 
depending on the distribution of variables.  Simple univariate/bivariate tests were conducted using t tests, 
Wilcoxon rank sum tests, ANOVA, Pearson χ2 or Fisher exact tests.   The association between total 
cholesterol, HIV infection, and change in cognitive score was examined using mixed-effects models with 
interaction terms for total cholesterol with time, HIV infection with time, and their joint interaction with 
time; total cholesterol was analyzed as a time-varying covariate.  A quadratic model was used to allow for 
potential acceleration in the rate of decline.  Continuous variables included baseline age at study entry, 
CES-D score, and IQ score; CD4 cell count was examined as a time-varying covariate. Smoking and HIV 
infection were analyzed as binary covariates.  A backwards elimination procedure was used to identify 
significant longitudinal relationships among predictors (P <0.05 cut-off).  The effect of APOE ε4 allele 
was explored in an independent mixed-effects model, with adjustment for the same covariates.  APOE ε4 
status was modeled as a categorical covariate (ε4 carrier, ε4 noncarrier, and unknown/ε2 homozygotes).  
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The decision to categorize the ε2 allele separately was made prior to analysis given its protective cognitive 
effects which may falsely underestimate cognitive decline in ε4 noncarriers [22].  Random predictors were 
correlated intercepts and linear slopes of time. Analyses were performed using SAS version 9.3 (SAS 
Institute, Cary, NC).   
 
Results 
Clinical Characteristics 
Clinical characteristics of the study cohort are shown in Table 1 (N= 789 men; 273 HIV+, 516 HIV-). The 
median age was 51 years at study entry (IQR: 50-55 years) with a mean follow-up of 6.3 years.  Eighty-one 
percent self-identified as non-Hispanic white, and 14% as black.  HIV+ and HIV- men had similar 
proportions with >12 years of education (P=0.35).  HIV+ men had higher mean baseline CES-D scores 
(9.7 vs. 8.5) and greater proportion with scores ≥16 (22% vs. 18%; P=0.08), a cut-off for high depressive 
symptoms. The median CD4 count was 514 at baseline and median nadir CD4 count was 387 cells/ml 
(IQR: 265-536) in follow-up; 70% maintained viral suppression (<50 copies/ml with ≤2 blips, blip ≥400 
copies/ml; Supplementary Figure 1).  Baseline total cholesterol and LDL levels were similar between 
groups, while HIV+ men had higher triglycerides and lower HDL than controls (P<0.001).  Among HIV+ 
men, 51% were on a statin for at least one year. 
Lipids and Cognitive Decline 
Time-related terms reflecting the association between total cholesterol levels and cognitive decline 
between ages 50-65 years are summarized in Table 2.  While the estimated rate of cognitive decline 
accelerated with increasing cholesterol levels in both groups, HIV+ men had a faster rate of decline 
compared to HIV- controls (P=0.003; Figure 2).  Figure 2 depicts the estimated annual rate of decline for 
a 50 year old man with and without HIV infection, illustrating two main findings: 1) On average, HIV+ 
men with higher total cholesterol levels have faster rates of cognitive decline than HIV+ men with lower 
levels; 2) The rate of cognitive decline in HIV+ men ages 50-65 years is differentially modified by 
cholesterol compared to HIV- men of the same age, IQ, baseline CES-D score, smoking status, and CD4 
count.  Given that higher cholesterol levels in HIV+ men were marginally associated with better cognitive 
scores at the intercept (P=0.05; Supplementary Table 2), deleterious effects of elevated cholesterol most 
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likely occurred after age 50.  Older age and baseline CES-D scores correlated with lower cognitive scores; 
IQ was associated with higher scores (Supplementary Table 2).   
In post-hoc analyses, total cholesterol was replaced with time-varying LDL, HDL, or log10 triglycerides, 
and associations with cognitive scores examined. Higher LDL and triglycerides were associated with a 
steeper slope of cognitive decline, while elevated HDL levels attenuated the rate of cognitive decline in 
HIV+ men (Figure 2 and Table 2).  The association between total cholesterol and decline in specific 
cognitive domains was examined in secondary analyses for composite scores of executive function, 
perceptual speed, verbal memory, attention and working memory, and motor speed.  Higher total 
cholesterol was associated with a steeper slope of decline in attention and working memory (P < 0.001), 
and marginal significance for verbal memory (P=0.05; Supplementary Table 2).   Additionally, the 
association between cholesterol level and the rate of decline among HIV+ subjects remained significant 
after the exclusion of two subjects with baseline cognitive z-score <-2 (data not shown). 
APOE ε4 Allele and Cognitive Decline 
Cohort characteristics of APOE ε4 carriers and noncarriers were similar to the larger study cohort 
(Supplementary Table 3), and ε4 genotype frequencies were comparable between groups (Figure 3A).    
Among HIV+ ε4 carriers vs. noncarriers, there were no differences in median baseline CD4 count, CD4 
nadir during follow-up, or ART medications used, but HIV+ ε4 carriers had higher baseline triglyceride 
levels (P<0.001).  While longitudinal decline in cognitive scores was observed among all HIV+ 
individuals, the rate of decline accelerated among HIV+ APOE ε4 carriers (P=0.01; Table 3).  Divergent 
estimated slopes in Figure 3B illustrate that the estimated cognitive trajectory for HIV+ ε4 carriers 
deviates rapidly from HIV+ ε4 noncarriers and HIV- controls between ages 50-65.  Given that there were 
no significant differences in the intercept between HIV+ carriers and noncarriers at study entry 
(Supplementary Table 4), cognitive decline for HIV+ ε4 carriers is expected to start after age 50.  In post-
hoc analyses accelerated rate of decline in perceptual speed, but no other cognitive domains, was 
estimated for HIV+ ε4 carriers  (P= 0.03; Supplementary Table 4).    
Given that cholesterol levels and APOE ε4 genotype was associated with cognitive decline in HIV+ men, 
we next examined whether these covariates interact to influence the rate of decline. The 3-way interaction 
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term between HIV infection, cholesterol, and time (P=0.002; Table 3) remained significant for cognitive 
decline among HIV+ APOE ε4 carriers.  While accelerated rates of decline were estimated among HIV+ 
APOE ε4 carriers vs. noncarriers (P<0.01), the annual rate of decline among ε4 carriers was not further 
modified by cholesterol levels (P=0.9; Figures 3C and D, Table 3, and Supplementary Table 5).  Thus, 
cholesterol levels and presence of the ε4 allele have independent effects on cognitive decline in HIV+ 
subjects, and do not substantially influence their respective associations.  
Discussion 
In this prospective study, elevated cholesterol, LDL, and triglyceride levels were associated with faster 
rates of cognitive decline in ART-adherent HIV+ men ages 50-65, while higher HDL attenuated cognitive 
decline.  The APOE ε4 genotype was associated with accelerated cognitive decline in HIV+ ε4 carriers 
over age 50, approximately a decade earlier than reported for HIV- ε4 carriers [23], suggesting that the 
interaction between treated HIV-infection and the ε4 genotype is a significant risk factor for earlier onset 
of cognitive decline.  Cholesterol levels and the APOE ε4 genotype had independent effects on the rate of 
decline among treated HIV+ but not HIV- men, and are therefore unlikely to be redundant risk factors.  In 
aggregate, these findings suggests that control of dyslipidemia may reduce the risk of midlife cognitive 
decline in aging PLWH on ART, and the APOE ε4 genotype likely influences cognitive trajectories via 
mechanisms distinct from its effects on lipid metabolism.  
HIV+ individuals are at increased risk for dyslipidemia due to HIV infection and ART, and have higher 
rates of cardiovascular disease and metabolic syndrome [8, 36]. Consistent with previous studies, 
triglyceride levels were higher, while HDL levels were lower in HIV+ vs. HIV- subjects in the study cohort.  
We tested the relationship between time-varying cholesterol levels and cognitive decline, and showed that 
for every 10 mg/dl increase in total cholesterol or LDL between ages 50-65, the rate of cognitive decline 
among HIV+ men increased.  We also demonstrated a positive relationship between time-varying HDL 
levels and longitudinal cognitive performance in HIV+ subjects. While published reports on the 
relationship between lipids and cognitive decline in the general population are mixed [37], the association 
between HDL and higher cognitive scores in midlife HIV+ men is similar to findings in older HIV-
uninfected cohorts  [38, 39].  HDL-like lipoproteins are found in CSF, are lower in those with AD or APOE 
ε4, and may be protective against cognitive decline [37]. HDL is proposed to play a role in mitigating 
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oxidative stress, metabolizing oxidized lipids, and reducing LDL-induced inflammation [40].  Together 
with findings from preceding studies demonstrating alterations in CSF lipid metabolism among HIV+ 
adults [41, 42], these analyses highlight the importance of future investigation to identify mechanisms by 
which altered lipids affect cognitive aging and potential strategies for therapeutic intervention. 
While our findings suggest that the APOE ε4 allele has a substantial effect on cognitive decline in older 
men with treated HIV infection, accelerating a downward trajectory after age 50, they differ from those of 
two previous longitudinal studies [26, 32].  Burt et. al. did not identify an association between the APOE 
ε4 allele and HIV-associated dementia in subjects on early ART regimens and Becker et. al. recently 
reported no association between the Ԑ4 allele and time to impairment or death. However, there are key 
methodological differences between study designs that should be taken into account when comparing the 
aforementioned results to the present study.  We studied ART-adherent HIV+ men over age 50, included 
HIV-controls well-matched for demographics and lifestyle factors, and allowed for acceleration in the rate 
of decline.  Our model predicts that while all groups are estimated to decline over time, there is a complex, 
nonlinear relationship between time and cognitive performance among older HIV+ ε4 carriers. Statistical 
models in prior longitudinal studies relied on assumptions that the relationship between predictors, time, 
and risk for cognitive impairment remains constant. As such, time or age-dependent effects of the ε4 
allele may have been underestimated in later follow-up.   
The lack of biomarkers specific for HAND or cognitive aging has resulted in controversy regarding 
accurate identification of at-risk HIV+ individuals with undetectable plasma HIV-1 RNA levels.  Our 
findings suggest that dyslipidemia and ε4 allele are risk factors for midlife cognitive decline in ART-
treated HIV+ adults over age 50.  In addition to its role in Aβ homeostasis, APOE modulates 
neuroinflammation and oxidative injury in an isoform-specific manner [43, 44]; these effects may be 
augmented in aging PLWH, especially given that HIV-related metabolic syndrome and abdominal obesity 
are associated with CSF immune activation markers and cognitive impairment [8, 45].  Superimposed 
cognitive aging effects related to dyslipidemia or ε4 genetic susceptibility, HIV-related 
neuroinflammation, and oxidative injury may increase vulnerability to midlife cognitive decline among 
ART-suppressed HIV+ individuals. Total cholesterol levels did not further moderate decline in HIV+ 
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APOE ε4 carriers, suggesting that cholesterol and ε4 allele have independent effects on cognitive decline 
via mechanisms that may involve cerebrovascular disease, in addition to other mechanisms.   
This study has several limitations, including those inherent to longitudinal observational studies such as 
selection, survivorship, and severity bias reflected in characteristics of the MACS study population.  These 
findings require replication in study populations with other demographic characteristics.  The study was 
limited to men, predominantly with > 12 years education.  Epidemiological studies report greater risk of 
clinical conversion from healthy aging to mild cognitive impairment or AD in female APOE ε4 carriers 
compared to males [46], highlighting the need for similar analyses in HIV+ women. Low education level 
is a known predictor for decline to symptomatic HAND [35] and higher educational attainment may 
provide some protection against effects of the ɛ4 allele by increasing cognitive reserve.  Nonetheless, 
despite high education levels, HIV+ men remained vulnerable to faster rates of decline compared to HIV- 
controls in the presence of high cholesterol or the ε4 allele. 
Our findings suggest that clinical management of dyslipidemia in ART-adherent HIV+ individuals may 
reduce the risk of midlife cognitive decline, and the window of opportunity likely occurs at a younger age 
than in the general population. A current consideration for adjuvant treatment is statins. Statins block 
conversion of 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor for cholesterol, and 
have pleiotropic effects including reducing inflammatory responses and improving endothelial function. 
Statins have not reduced AD risk in several randomized clinical trials [47], but these results should be 
interpreted with caution when considering management of dyslipidemia in HIV infection.  Statins 
primarily target LDL, while cognitive impairment shows stronger associations with HDL [38, 39].  Altered 
HDL functionality is associated with immune activation in HIV infection [48], and findings presented 
here estimate that higher HDL levels attenuate cognitive decline.  Given impressive efforts that have 
improved survival among HIV+ individuals, this study underscores the importance of lipid profiles and 
APOE ε4 allele to midlife cognitive health in aging HIV+ adults and suggest that clinical management of 
dyslipidemia may be an effective adjunctive strategy to reduce cognitive decline in ART-treated HIV+ 
individuals. 
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Table 1: Cohort Characteristics 
 
      All Subjects HIV- HIV+ P value 
 
No. of patients 
 
789 
 
516 
 
273 
NA 
Length of Follow-up, mean (SD), years  6.3 (3.2) 6.0 (3.2) 6.8 (3.1) <0.01 
 
Demographics  
 
 
  
Baseline Age, median (IQR) years 51.0 (50-55) 51.5 (50-55) 50.0 (50-52) <0.001 
Race, No. (%) 
 
 
 
  
White 636 (80.6) 429 (83.1) 207 (75.8) <0.01 
Black  112 (14.2) 62 (12.0) 50 (18.3)   
Hispanic or Latino 21 (2.7) 15 (2.9) 6 (2.2)   
Other 15 (1.9) 10 (1.9) 5 (1.8)   
Education >12 years, No. (%) 702 (89.0) 463 (89.7) 239 (87.5) 0.35 
Shipley WAIS IQ- Equivalent, mean (SD) 109.5 (8.9) 109.1 (10.7) 106.5 (11.3) <0.01 
 
Depression Profile 
   
  
Baseline CES-D Score, mean (SD) 8.9 (9.6) 8.5 (9.5) 9.7 (9.8) 0.13 
Baseline CES-D Score ≥ 16, No. (%) 151 (19.1) 92 (17.8) 59 (21.6) 0.08 
 
Substance Use, No. (%)  
 
   
Smoking (Highest use on ≥ 2 visits) 
 
 
 
0.26 
None 574 (72.8) 386 (74.8) 188 (68.9)   
<1/2 pack per day 66 (8.4) 38 (7.4) 28 (10.3)   
1/2 - 2 packs per day 146 (18.5) 90 (17.4) 56 (20.5)   
Alcohol (Highest use on ≥ 2 visits)1 
 
  
0.07 
None-Light 111 (14.1) 71 (13.8) 40 (14.7)   
Occasional-Moderate 566 (71.7) 379 (73.4) 187 (68.5)   
Heavy/Binge 100 (12.7) 55 (10.7) 45 (16.5)   
 
Baseline Lipid Profile, Mean (SD), mg/dl  
  
  
Total Cholesterol  197.1 (40.4) 195.1 (36.3) 201.1 (47.4) 0.11 
LDL 115.4 (34.8) 117.2 (33.7) 111.9 (36.8) 0.08 
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HDL 47.6 (13.3) 49.0 (12.4) 44.8 (14.4) <0.001 
Triglycerides 161.0 (123.1) 136.3 (95.5) 212.7 (154.8) <0.001 
 
Lipid-lowering Medication, No. (%)
3
  
  
  
Statin 304 (38.5) 164 (31.8) 140 (51.3) <0.001 
Fibrate 78 (9.9) 23 (4.5) 55 (20.1) <0.01 
Niacin 38 (4.8) 21 (4.1) 17 (6.2) 0.24 
 
HCV Antibody Positive, No. (%) 74 (9.4) 35 (6.8) 39 (14.3) <0.01 
 
HIV Disease Characteristics, Median 
(IQR) 
   
  
Baseline CD4 (cells/µl)
2
 805 (569-1055) 951 (743-1174) 514 (333-684) <0.001 
CD4 nadir (cells/µl) in study 623 (431-840) 726 (580-916) 387 (265-536) <0.001 
Baseline HIV-1 RNA VL  
(copies/ml)
2
 
  
40 (40-40) 
  
Baseline CPE Score
2
 
  
7.0 (6-9)   
 
Antiretroviral Medication, No. (%)
3
 
   
  
Azidothymidine 
  
95 (34.8)   
Efavirenz 
  
114 (41.8)   
Protease Inhibitor 
  
190 (69.6)   
ddI, d4T, ddC 
  
106 (38.8)   
Abacavir     96 (36.2)   
  
P values <0.05 were considered significant. 
 1 Alcohol Use: Light= <1 drink/week; Occasional-Moderate= 1-14 drink(s)/week; Heavy=  >14/week, Binge=  ≥5 drinks/one sitting/month 
 2 Baseline values: first visit or within 6 months of study period  
   
3 
Self-reported Lipid-lowering medication and ART medication used on ≥ 2 visits  
Abbreviations: SD= standard deviation; IQR:  Quartile1 – Quartile3; NA= not applicable; CES-D= Center for Epidemiological Studies Depression Scale; 
LDL= low-density lipoprotein; HDL=high-density lipoprotein; HCV= hepatitis C virus; HIV= human immunodeficiency virus; VL= viral load; CPE= CNS 
Penetration Effectiveness[49]; ddI= Didanosine; d4T= Stavudine; ddC=Zalcitabine 
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Table 2:  Associated Effect of Lipids on the Annual Rate of Cognitive Decline  
Total Cholesterol  Estimate SE P value 
HIV+ * Years in Study 0.0613 0.0226 0.007 
Total Cholesterol (10 mg/dl) * Years in Study 0.0040 0.0016 0.112 
Total Cholesterol (10 mg/dl) * Years in Study * Years in Study -0.0003 0.0001 0.043 
Total Cholesterol (10 mg/dl) * HIV+ * Years in Study -0.0034 0.0011 0.003 
    LDL 
   HIV+ * Years in Study 0.0423 0.0170 0.013 
LDL (10 mg/dl) * Years in Study 0.0022 0.0018 0.995 
LDL (10 mg/dl) * Years in Study * Years in Study -0.0002 0.0002 0.371 
LDL (10 mg/dl) * HIV+ * Years in Study -0.0043 0.0014 0.002 
    HDL 
   HIV+ * Years in Study -0.0460 0.0202 0.024 
HDL (10 mg/dl) * Years in Study -0.0006 0.0053 0.390 
HDL (10 mg/dl) * Years in Study * Years in Study 0.0001 0.0005 0.819 
HDL (10 mg/dl) * HIV+ * Years in Study 0.0098 0.0043 0.022 
    Triglycerides (Log10 mg/dl) 
   HIV+ * Years in Study 0.0949 0.0450 0.036 
Triglycerides * Years in Study 0.0599 0.0259 0.121 
Triglycerides * Years in Study * Years in Study -0.0047 0.0023 0.041 
Triglycerides * HIV+ * Years in Study -0.0424 0.0205 0.039 
Adjusted for age, Shipley WAIS IQ- Equivalent Score, and CES-D at study entry, smoking status, and 
CD4 count. Lipid estimates except triglyceride levels were interpreted in 10 mg/dl increments. A negative 
estimate indicates a steeper slope of cognitive decline.  
R2 for fixed effects= 0.25, P<0.001; R2 including random terms=0.94, P<0.0001
 
The squared Pearson correlations of predicted values from fixed or fixed and random terms versus actual 
values of the dependent variable indicate the percent of variance accounted for by predictors (reported for  
total cholesterol).   
Abbreviations: LDL= low density lipoprotein, HDL= high density lipoprotein, SE= standard error,  
* indicates an interaction 
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Table 3:  Effect of APOE ε4, Total Cholesterol, and HIV Infection on the Rate of Cognitive Decline  
 
 
 
 
Model 1 (N=542): Estimate SE P value 
HIV+ * Years in Study  -0.0104 0.0168 0.266 
HIV+ * Years in Study * Years in Study  0.0002 0.0016 0.003 
APOE ε4 Carrier * Years in Study  0.0227 0.0243 0.022 
APOE ε4 carrier * Years in Study * Years in Study  -0.0008 0.0022 0.002 
HIV+ *  APOE ε4 carrier * Years in Study 0.0519 0.0355 0.300 
HIV+ *APOE ε4 carrier * Years in Study * Years in Study -0.0106 0.0035 0.010 
    Model 2 (N=245): 
   APOE ε4 Carrier * Years in Study -0.02388 0.06127 0.8136 
HIV+ * Years in Study 0.1452 0.04568 0.0005 
Total Cholesterol(10 mg/dl) * Years in Study 0.00214 0.00125 0.8417 
Total Cholesterol (10 mg/dl) * HIV+ * Years in Study  -0.0056 0.00184 0.0021 
APOE ε4 Carrier * HIV+ * Years in Study  0.0266 0.07136 0.71 
APOΕ4 carrier * HIV+* Years in Study * Years in Study   -0.01099 0.003421 0.0058 
APOE ε4 Carrier * Total Cholesterol (10 mg/dl) * Years in Study  0.00192 0.00252 0.3598 
APOE ε4 Carrier * HIV+ * Total Cholesterol (10 mg/dl) 
*Years in Study -0.00004 0.000308 0.897 
 Adjusted for age at study entry, Shipley WAIS IQ- Equivalent Score, CES-D at study entry, smoking status, and 
CD4 count. Total cholesterol was interpreted in 10 mg/dl increments. APOE ε4 was modeled as a categorical 
variable (ε4 carrier, ε4 noncarrier or unknown/ε2 homozygous) in Model 1.  Model 2 included subjects with 
known APOE ε4 genotype.    
 Model 1: R2 for fixed effects= 0.26, P<0.001; R2 including random terms=0.97, P<0.0001 
Model 2: R2 for fixed effects= 0.28, P<0.001; R2 including random terms=0.93, P<0.0001 
 The squared Pearson correlations of predicted values from fixed or fixed and random terms versus actual values 
of the dependent variable indicate the percent of variance accounted for by predictors.   
Abbreviations: APOE= Apolipoprotein E, CES-D= Center for Epidemiological Studies Depression Scale, 
IQ =Shipley WAIS IQ- Equivalent Score, SE= standard error, * indicates an interaction 
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Figures 
 
Figure 1:  Selection of the HIV- and HIV+ Study Cohort 
Subject enrollment and sequential application of inclusion and exclusion criteria to define the study 
population. *Subjects with neuropsychological scores between ages 45-49 years and 50-65 years were 
counted towards both groups.  Abbreviations: CNS= central nervous system; OI= opportunistic infections 
(lymphoma, progressive multifocal leukoencephalopathy, toxoplasmosis, or cryptococcus); HCV= 
hepatitis C virus; HIV= human immunodeficiency virus; NP= neuropsychological; ART= antiretroviral 
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therapy; VL= HIV-1 viral load; Heavy drug use= crack, cocaine, or heroin use >50% of visits during study 
period.  
 
Figure 2: Higher Total Cholesterol, LDL, and Triglycerides are Associated with Faster 
Rates of Cognitive Decline, While Higher HDL Levels Attenuate Decline in ART-treated 
HIV+ Men 
Estimated slopes in neurocognitive scores according to total cholesterol, low-density lipoprotein (LDL), 
high-density lipoprotein (HDL), and log10 triglyceride levels stratified by HIV infection, and categorized 
by National Cholesterol Education Program guidelines are shown.  The slopes are estimated for a man 
with study entry age of 50, and cohort mean IQ score 108, baseline CES-D score 9, and CD4 count held at 
800 cells/ml.  The x-axis is time in study (years) centered at zero for the first visit after age 50, and y-axis 
is the change in cognitive performance from the baseline score.  There is an accelerated rate of age-related 
decline in the cognitive score as total cholesterol and triglycerides levels increase in HIV- and HIV+ men, 
an effect not observed for LDL or HDL levels.  Higher total cholesterol (P=0.003), LDL (P=0.002), and 
triglycerides (P=0.04) levels in HIV+ men are associated with a steeper slope of cognitive decline during 
the study, while higher HDL levels attenuated the rate of decline (P=0.02).   
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Figure 3: APOE ε4 Allele and Total Cholesterol Have Independent Effects on Cognitive 
Decline in ART-treated HIV+ Men 
The distribution of APOE genotypes among HIV+ and HIV- subjects (A), and estimated slopes for 
cognitive scores for APOE ε4 allele and HIV infection status are shown (B).  Cognitive scores for subjects 
with unknown or ε2/ε2 genotypes are shown in grey (B). Among those with ε4 genotype, cognitive decline 
for HIV+ ε4 carriers (C) and noncarriers (D) modified by total cholesterol are shown. The annual rate of 
decline is estimated for a man with baseline age 50, and cohort mean IQ score 108, baseline CES-D score 
9, and CD4 count held at 800 cells/ml.  APOE ε4 carriers had lower baseline cognitive scores than 
noncarriers (P=0.03), an association that was not modified by HIV infection (P=0.14).  HIV+ APOE ε4 
carriers showed accelerated decline in cognitive scores between ages 50-65 and the rate of accelerated 
decline was faster than predicted for HIV+ noncarriers (P=0.01).  Increasing total cholesterol levels was 
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associated with faster rates of decline among HIV+ ε4 noncarriers (P<0.01), while the accelerated rate of 
decline in HIV+ ε4 carriers was not further modified by cholesterol (P=0.9).   
 
Supplementary Figure 1:  Longitudinal HIV Plasma Viral Loads and CD4 Counts for 279 
HIV+ Subjects 
Lasagna plots visualizing HIV-1 plasma viral loads (left panel) and CD4 counts (right panel) for each 
subject over time.  Subjects’ person-visits are represented in a single row. The vertical order of the lasagna 
plots is based on relative viral load suppression, with subjects demonstrating the greatest variability in 
HIV viral load at the bottom of the plot.  Increasing viral load is depicted with increasing color intensity 
(left).  CD4 counts are categorized by relevant clinical cutoffs with bright yellow indicating CD4 <200 
cells/ml (right).  Grey values represent missing viral load or CD4 count during a study visit where 
additional data was available; black dots indicate self-reported ART use (left).    
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Supplementary Data 
Methods 
Study population details 
Details of the study design, demographic characteristics, and enrollment patterns among different 
recruitment periods (1984-85, 1987-91, 2001-2003) for the MACS have been previously described in 
detail [49, 50].  All subjects were invited to participate in the NP study at the time of their regular MACS 
visit irrespective of HIV serostatus or cognitive symptoms until the maximum allowable cohort for that 
center was recruited.  For the present study, exclusion criteria were subjects outside the age of interest 
(45-65 years old), history of CNS opportunistic infections or CNS lymphoma, self-reported cocaine, crack 
or heroin use at >50% of visits during the study period, HIV seroconversion date unknown or occurring 
within the study window, < 2 visits with NP data, and missing data required for matching.  Among HIV+ 
men, additional exclusion criteria were ART nonadherence (defined as self-reported ART use  < 95% of 
study visits), reported not taking ART at more than one study visit, study entry visit VL ≥ 400 copies, and 
all subsequent visits with VL ≥ 400 copies/ml. CNS penetration effectiveness (CPE) score was calculated 
for each visit based on the 2010 CPE table [49].  
 
Outlier algorithm and missing data 
Outliers on NP tests were defined as having z-scores < -5; if no identifiable reason for an outlying value 
was determined, values were imputed using the average of NP scores from the prior and subsequent visits 
within 6 months.  When elapsed time recorded for NP tests was greater than the tests’ maximum time per 
instructions, values were imputed to maximum time allowed for the test. A total of 176 person-visits met 
above criteria and values for these visits were imputed (0.35% of person-visits in the observation period).  
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Supplementary Table1: List of 15 Cognitive Tests Categorized in Domains
1
 
DOMAIN INDIVIDUAL NEUROCOGNITIVE TESTS 
 
Executive Function 
 
Trail-Making Test Part B 
Stroop Interference Task 
 
Perceptual Speed 
 
Symbol Digit Modalities Test 
Stroop Color Naming 
Stroop Word Naming 
Trail-Making Test Part A 
 
Verbal Memory -Learning and Retrieval 
 
RAVLT Sum of Trials 1 to 5 
RAVLT-Immediate Recall 
RAVLT-Delayed Recall 
 
Attention/Working Memory 
 
CALCAP-Mean Simple Reaction time (1) and Mean Complex Reaction Time (3,4,14) 
 
Motor/Processing Speed 
 
Grooved Pegboard (both hands) 
 
1To reduce floor and ceiling affects, we created summary measures of cognitive function. Briefly, each summary measure was calculated by converting individual tests to z-scores using 
the baseline mean and SD from a cohort of HIV- and HCV- subjects, ages 45-49 years old without heavy drug use. The signs for some timed tests were changed so that higher z-scores 
always denote better performance.  We averaged z-scores for the 15 tests to create the cognitive summary score with the requirement that all scores be present.  The individual domain 
scores were created in a similar fashion.  
 
Abbreviations: RAVLT=  Rey Auditory Verbal Learning Test;  CALCAP= California Computerized Assessment Package http://www.calcaprt.com/calcap.htm 
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   Supplementary Table 2:  Effect of Total Cholesterol and HIV Infection on the Annual Rate of Cognitive Decline 
  Cognitive Summary Executive Function  Perceptual Speed Verbal Memory Attention/Working Memory Motor Speed 
  β SE 
P 
value β SE 
P 
value β SE 
P 
value β SE 
P 
value β SE P value β SE 
P 
value 
Intercept -0.8941 0.528     0.091 -1.9961 0.715 0.006 -1.3326 0.637 0.037 -0.772 0.7748 0.320 -0.6395 0.6555 0.330 1.0682 0.8415 0.205 
Age at Study 
Entry -0.04255    0.008222     <.0001 -0.05695 0.011 <.0001 -0.04907 0.010 <.0001 -0.05134 0.01187 <.0001 -0.02016 0.01004 0.045 -0.07055 0.01311 <.0001 
IQ 0.02639    0.002608     <.0001 0.04022 0.003 <.0001 0.03257 0.003 <.0001 0.02945 0.003607 <.0001 0.01808 0.003216 <.0001 0.02215 0.004018 <.0001 
CES-D Score at 
Study Entry -0.00597    0.002699     0.027 -0.00995 0.003 0.005 -0.01049 0.003 0.001 -0.00039 0.003868 0.920 -0.01033 0.003292 0.002 -0.01192 0.004344 0.006 
Smoker -0.08384     0.06093     0.17 -0.04176 0.082 0.609 -0.06998 0.075 0.349 -0.06537 0.08788 0.457 -0.00827 0.07385 0.911 -0.1856 0.09686 0.056 
CD4 Count 0.000277    0.000129         0.033 0.000345 <0.001 0.106 0.000296 <0.001 0.071 0.000404 0.000256 0.114 0.000309 0.000196 0.116 0.000341 0.000269 0.206 
CD4 Count * 
CD4 count -1.17E-7 0 <.0001 -1.68E-07 0 <.0001 -1.32E-07 0 <.0001 -1.48E-07 0 <.0001 -1.61E-07 0 <.0001 -2.10E-07 0 <.0001 
HIV Infection -0.2217      0.1234     0.073 -0.03788 0.202 0.852 -0.06751 0.158 0.669 -0.2724 0.2479 0.272 -0.5679 0.1841 0.002 -0.348 0.2651 0.190 
Total Cholesterol 
(10mg/dl) -0.00049    0.000454     0.912 0.01041 0.008 0.025 0.00206 0.006 0.387 -0.0163 0.00972 0.352 -0.0179 0.00702 0.439 -0.0057 0.01034 0.738 
Total Cholesterol 
(10mg/dl) * HIV 
Infection 0.01058    0.00540     0.051 0.00373 0.009 0.687 0.00303 0.007 0.665 0.0197 0.01157 0.089 0.02793 0.00846 0.001 0.00656 0.01232 0.595 
Years in Study -0.06829     0.03077     0.187 0.03266 0.053 0.486 -0.00799 0.04 0.639 -0.1502 0.06719 0.067 -0.1452 0.04948 0.064 -0.1407 0.07149 0.081 
Years in Study * 
Years in Study 0.003250    0.002771     0.241 -0.00167 0.005 0.725 -0.00291 0.004 0.412 0.01802 0.006033 0.003 0.003198 0.00451 0.479 0.003278 0.006391 0.608 
HIV Infection * 
Years in Study 0.06134     0.02256     0.007 0.002474 0.039 0.949 0.05021 0.03 0.088 0.07245 0.04812 0.133 0.1194 0.03533 0.001 0.0504 0.05298 0.342 
Total Cholesterol 
(10 mg/dl) * 
Years in Study 0.00398    0.00155     0.112 -0.0002 0.003 0.970 0.00064 0.002 0.775 0.00874 0.00339 0.043 0.00618 0.00252 0.191 0.00571 0.00036 0.220 
Total Cholesterol 
(10 mg/dl) * 
Years in Study 
 * Years in Study -0.0003    0.00014     0.043 -6.94E-05 <0.001 0.777 3.88E-05 <0.001 0.832 -0.0009 0.00031 0.003 -0.0002 0.00024 0.390 -0.0004 0.00033 0.202 
Total 
Cholesterol (10 
mg/dl)* HIV 
serostatus * 
Years in Study -0.0034    0.00112     0.003 0.00017 0.002 0.930 -0.0023 0.001 0.110 -0.0047 0.00241 0.051 -0.0062 0.00178 0.001 -0.0032 0.00263 0.217 
Mixed models were adjusted for age at study entry, Shipley WAIS IQ- Equivalent Score, CES-D at study entry, smoking status, CD4 count (linear and quadratic term).  Cholesterol 
estimates were interpreted in 10 mg/dl increments. A negative estimate indicates a steeper slope of cognitive decline 
Abbreviations: CES-D= Center for Epidemiological Studies Depression Scale, IQ =Shipley WAIS IQ- Equivalent Score, β=Estimate, SE= standard error, * indicates an interaction 
 
 
25 
 
Supplementary Table 3:  APOE Clinical Characteristics 
  All Subjects 
HIV- Ε4 
NonCarrier 
HIV- Ε4 
Carrier 
HIV+ Ε4 
Noncarrier 
HIV+ Ε4 
Carrier 
P value 
P value between 
HIV+ noncarrier 
vs. HIV+ carrier 
P value 
between 
noncarrier 
vs. carrier 
No. of  patients 344 186 50 77 31 NA     
Length of Followup, mean (SD), years  7.2 (3.0) 6.8 (2.7) 6.8 (3.3) 7.7 (3.0) 6.7 (3.3) 0.13 0.13 0.3844 
Demographics             
  Baseline Age, median (Q1-Q3) years 50.0 (50-54) 51.0 (50-54) 51.0 (50-53) 50.0 (50-51) 50.5 (50-54) 0.03 0.0684 0.9357 
Race/Ethnicity, No. (%)             
  White 292 (84.9) 165 (88.7) 43 (86.0) 57 (74.0) 27 (87.1) 0.102 
  Black  38 (11.1) 12 (6.5) 7 (14.0) 16 (20.8) 3(9.7)   
  Hispanic or Latino 9 (2.6) 5 (2.7) 0 3(3.9) 1 (3.2)   
  Other 5 (1.5) 4 (2.2) 0 1 (1.3) 0   
  Education >12 years, No. (%) 344  (100) 186 (100) 50 (100) 77 (100) 33 (100) NA 
  Shipley WAIS IQ- Equivalent, mean (SD) 109.5 (8.9) 111.2 (7.7) 107.1 (9.4) 107.3 (10.0) 110.0 (9.2) 0.09 0.22 0.3475 
Depression Profile             
  Baseline CES-D Score, mean (SD) 8.2 (9.1) 7.8 (8.7) 6.9 (10.2) 9.6 (9.4) 9.5 (9.1) 0.18 0.99 0.6237 
Baseline CES-D Score ≥ 16, No. (%) 60 (17.4) 31 (16.7) 7 (14.0) 15 (19.5) 7 (21.2) 0.22 0.5616 0.9584 
Substance Use, No. (%)             
  Smoking (Highest use on ≥ 2 visits)           0.7 
  None 270 (78.5) 148 (79.6) 35 (70.0) 61 (79.2) 26 (83.9)   
   <1/2 pack per day 30 (8.7) 14 (7.5) 6 (12.0) 7 (9.1) 3 (9.7)   
  1/2 - 2 packs 44 (12.8) 24 (12.9) 9 (18.0) 9 (11.7) 2 (6.5)   
  Alcohol (Highest use on ≥ 2 visits)1           0.62 
  None 47 (13.7) 27 (14.5) 6 (12.0) 9 (11.7) 5 (16.1)   
  Occasional-Moderate 257 (74.7) 143 (76.9) 37 (74.0) 55 (71.4) 22 (71.0)   
  Heavy/Binge 40 (11.6) 16 (8.6) 7 (14.0) 13 (16.9) 4 (12.9)   
  Baseline Lipid Profile, Mean (SD)             
  Total Cholesterol 199.7 (36.2) 199.3 (34.2) 193.5 (30.6) 199.6 (41.5) 212.8 (41.3) 0.56 0.2009 0.8536 
LDL 119.6 (33.1) 122.0 (32.8) 121.4 (49.7) 115.6 (35.8) 115.0 (34.1) 0.37 0.9455 0.7329 
HDL 47.8 (13.3) 48.1 (12.2) 48.6 (12.9) 45.8 (11.4) 49.3 (23.0) 0.53 0.4861 0.4307 
Triglycerides 142.6 (96.2) 128.3 (76.2) 121.4 (49.7) 151.4 (71.5) 285.8 (216.8) <0.001 <0.001 0.05 
Lipid-lowering Medication, No. (%)3             
  Statin 143 (41.6) 64 (34.4) 21 (42.0) 40 (51.9) 18 (58.1) 0.013 
  Fibrate 34 (9.9) 6 (3.2) 5 (10.0) 14 (18.2) 9 (29.0) <0.001 
  Niacin 19 (5.5) 11 (5.9) 2 (4.0) 5 (6.5) 1 (3.2) 0.867 
  HCV Antibody Positive, No. (%) 16 (4.7) 5 (2.7) 3 (6.0) 6 (7.8) 2 (6.5) 0.003 0.5847 0.545 
HIV Disease Characteristics, Median 
(Q1-Q3)             
  Baseline CD4 (cells/ml)2   859 (604-1104) 948 (771-1153) 1072 (777-1268) 536 (346-743) 457 (331-630) <0.001 0.4821 0.846 
CD4 nadir (cells/ml) in observation 647 (458-862) 718 (575-1100) 804 (595-967) 387 (228-553) 407 (287-624) <0.001 0.5638 0.9913 
Baseline Log10 HIV RNA VL 
(copies/ml)2       1.6 (1.6-1.6) 1.6 (1.6-1.6) 0.72 NA NA 
Baseline CPE Score2       7.0 (6-9) 8.0 (6-9) 0.26 NA NA 
Antiretroviral Medication, No. (%)3             
  Azidothymidine       28 (36.4) 9 (29.0) 0.51 NA NA 
Efavirenz       33 (42.9) 20 (64.5) 0.056 NA NA 
Protease Inhibitor       56 (72.7) 18 (58.1) 0.171 NA NA 
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P values <0.05 were considered significant.   
1 Alcohol Use: Light= <1 drink/week; Occasional-Moderate= 1-14 drink(s)/week; Heavy=  >14/week, Binge=  ≥5 drinks/one sitting/month 
2 Baseline values: first visit or within 6 months of study  period  
3 Self-reported Lipid-lowering or ART medication used on ≥ 2 visits  
Abbreviations: SD= standard deviation; Q1-Q3:  Quartile1 – Quartile3; NA= not applicable; CES-D= Center for Epidemiological Studies  Depression Scale; LDL= low-density lipoprotein;  
HDL=high-density lipoprotein; HCV= hepatitis C virus; HIV= human immunodeficiency virus; VL= HIV-1 viral load; CPE= CNS Penetration Effectiveness; ddI= Didanosine; d4T= Stavudine; ddC=Zalcitabine 
ddI, d4T, ddC       34 (44.2) 13 (41.9) 1 NA NA 
Abacavir       29 (37.7) 17 (54.8) 0.132 NA NA 
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Supplementary Table 4: Effect of the APOE Ε4 allele and HIV Infection on Annual Rate of Cognitive Decline 
 
 
Cognitive Function Executive Function Perceptual Speed Verbal Memory Attention/Working Memory Motor Speed 
  β SE 
P 
value β SE P value β SE P value β SE P value β SE 
 
P 
value β SE P value 
Intercept -1.0077 0.5332 0.060 -1.8938 0.7121 0.008 -1.3487 0.6426 0.036 -0.8461 0.7612 0.267 -1.0148 0.6471 
 
0.118 0.9204 0.826 0.266 
Age at Study Entry -0.0426 0.0026 <.0001 -0.05531 0.01106 <.0001 -0.04861 0.01022 <.0001 -0.05508 0.003592 <.0001 -0.01867 0.01005 
 
0.064 -0.0701 0.01315 <.0001 
IQ 0.0268 0.0083 <.0001 0.04133 0.003405 <.0001 0.03314 0.003055 <.0001 0.02947 0.01198 <.0001 0.01734 0.003194 
 
<.0001 0.02204 0.00398 <.0001 
CES-D Score at Study 
Entry -0.0062 0.0027 0.021 -0.00949 0.003533 0.007 -0.00944 0.003267 0.004 -0.00042 0.003838 0.914 -0.01126 0.003275 
 
0.001 -0.01213 0.004295 0.005 
Smoker -0.1198 0.0602 0.047 -0.08532 0.07985 0.286 -0.1235 0.07356 0.094 -0.1042 0.08598 0.226 -0.03051 0.07255 
 
0.674 -0.1923 0.09431 0.042 
CD4 Count 0.0003 0.0001 0.021 0.00032 0.000194 0.100 0.000176 0.000151 0.244 0.000329 0.000239 0.169 0.000361 0.000183 
 
0.048 0.000377 0.000245 0.125 
CD4 Count * CD4 
count 
-
1.10000
E-07 0 <.0001 -1.37E-07 0 <.0001 -6.63E-08 0 <.0001 -1.09E-07 0 <.0001 -1.83E-07 0 
 
<.0001 -2.16E-07 0 <.0001 
HIV Infection 0.0236 0.0829 0.539 0.05827 0.1157 0.373 0.1088 0.1026 0.803 0.159 0.1309 0.005 -0.03028 0.107 
 
0.907 -0.1296 0.1404 0.274 
APOE E4 carrier -0.2834 0.1352 0.032 -0.5901 0.1764 0.000 -0.4019 0.1591 0.003 -0.482 0.1952 0.288 0.05679 0.163 
 
0.236 -0.1837 0.2078 0.593 
HIV Infection * APOE 
E4 carrier 0.2259 0.1953 0.139 0.3937 0.2615 0.031 0.11 0.2361 0.037 0.6559 0.2887 0.025 0.09321 0.2362 
 
0.872 0.0968 0.3093 0.788 
Years in Study 0.0002 0.0110 0.014 -0.01803 0.01857 0.000 -0.01272 0.01429 0.004 0.03843 0.02432 0.565 -0.03702 0.01758 
 
0.157 -0.02473 0.0252 0.077 
Years in Study * Years 
in Study -0.0013 0.0011 <0.001 0.00064 0.001868 <.0001 -0.00085 0.001433 <.0001 -0.00311 0.00245 0.603 0.000789 0.001809 
 
0.098 -0.00537 0.002528 <.0001 
Years in Study * HIV 
Infection -0.0104 0.0168 0.266 0.02892 0.02837 0.017 -0.00734 0.02171 0.137 -0.04124 0.03678 0.021 -0.00778 0.02722 
 
0.099 -0.04815 0.03828 0.452 
Years in Study * Years 
in Study * HIV 
Infection 0.0002 0.0016 0.003 -0.0023 0.002745 0.001 0.001083 0.002096 0.014 0.003141 0.003581 0.233 -0.00045 0.002669 
 
0.030 0.003612 0.003707 0.872 
Years in Study * 
APOE E4 Carrier 0.0227 0.0243 0.022 0.05367 0.0413 0.003 0.06773 0.03153 0.000 0.0252 0.0537 0.507 -0.02599 0.03992 
 
0.032 0.02425 0.05579 0.540 
Years in Study * Years 
in Study * APOE E4 -0.0008 0.0022 0.002 -0.00157 0.00393 0.010 -0.00376 0.002986 0.000 -0.00134 0.005148 0.235 0.003692 0.003769 
 
0.020 -0.0013 0.005268 0.288 
HIV Infection * APOE 
E4 * Years in Study 0.0519 0.0355 0.300 0.02545 0.05972 0.474 0.0538 0.04564 0.277 -0.04608 0.07666 0.758 0.09662 0.05621 
 
0.221 0.03467 0.08193 0.775 
HIV Infection * 
APOE E4 * Years in 
Study * Years in 
Study -0.0106 0.0035 0.010 -0.00848 0.005731 0.212 -0.01095 0.00438 0.035 -0.00029 0.007365 0.981 -0.00998 0.005382 
 
0.179 -0.01001 0.008017 0.459 
 
P values <0.05 were considered significant 
Abbreviations: APOE= apolipoprotein E, CES-D= Center for Epidemiological Studies Depression Scale, IQ =Shipley WAIS IQ- Equivalent Score, SE= standard error,  
* indicates an interaction, Bold indicates statistical test of interest 
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Supplementary Table 5: Effect of Total Cholesterol and APOE on Annual Rate of Cognitive Decline 
    Neurocognitive Score 
  β SE Pvalue 
Intercept -0.5435 0.8214 0.509 
IQ 0.03346 0.004369 <.0001 
Baseline Age -0.06233 0.01233 <.0001 
Baseline CES-D Score -0.00628 0.003774 0.0972 
Smoker 0.01083 0.08889 0.9032 
APOE4 carrier -0.2 0.2395 0.9812 
CD4 0.000098 0.000196 0.6158 
CD4*CD4 -3.63E-08 0 <.0001 
HIV Infection -0.2988 0.2171 0.6371 
Total Cholesterol (10 mg/dl) -0.0011 0.00634 0.8783 
Total Cholesterol (10 mg/dl) * HIV+ infection 0.00597 0.00948 0.5295 
APOΕ4 carrier * HIV+ infection 0.3895 0.197 0.0495 
Total Cholesterol (10 mg/dl) * APOE4 carrier -0.0023 0.00937 0.8094 
Years in Study -0.0418 0.02907 0.2574 
Years in Study * Years in Study -0.00175 0.001143 <.0001 
Years in Study * APOE4 carrier -0.02388 0.06127 0.8136 
Years in Study * HIV Infection 0.1452 0.04568 0.0005 
Years in Study * Total Cholesterol (10 mg/dl) 0.00214 0.00125 0.8417 
Years in Study * Total Cholesterol (10 mg/dl) * HIV infection -0.0056 0.00184 0.0021 
Years in Study * APOE4 carrier * HIV infection 0.0266 0.07136 0.71 
Years in Study * Years in Study * APOE4 carrier * HIV infection -0.01099 0.003421 0.0058 
Years in Study * APOE4 carrier * Total Cholesterol (10 mg/dl) 0.00192 0.00252 0.3598 
Years in Study * APOE4 carrier * HIV Infection * Total Cholesterol (10 mg/dl) -0.00004 0.000308 0.897 
P values <0.05 were considered significant 
Abbreviations: APOE= apolipoprotein E, CES-D= Center for Epidemiological Studies Depression Scale, IQ =Shipley WAIS IQ- Equivalent Score, 
β=Estimate, SE= standard error, * indicates an interaction, Bold indicates statistical test of interest 
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Chapter Ib: 
Preliminary Studies on the Association between Statin Medications and Midlife Cognitive Decline 
in ART-Adherent HIV+ Men 
 
 (This work has not been submitted for publication) 
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Objective 
Hyperlipidemia or dyslipidemia is a pathologic cardiometabolic condition with important relevance for 
cognitive function (reviewed [51]).  In the Cardiovascular Risk Factors Aging and Dementia (CAIDE) 
study, midlife total cholesterol predicted cognitive impairment 21 years later [19], and in a population-
based study from the Kaiser Permanente Medical Care Program, high midlife cholesterol level increased 
the risk for Alzheimer’s Disease and Vascular Dementia [52].  While cholesterol-lowering agents such as 
statins are able to protect against stroke as shown in cohort studies, and the clinical trial, Stroke 
Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL)[53, 54], this has not translated to 
improved cognitive function in the general population [47].   
 
Statins have anti-inflammatory properties that include reduction of reactive oxygen species, and 
endothelial nitric oxide synthase.  Statin treatment of moncytes reduces CD11β expression and  inhibits 
cellular adhesion to the endothelium [55].  In animal studies, the number of leukocytes in atherosclerotic 
plaques is reduced with statin treatment even in the absence of effects on plasma lipid levels [56].  In 
chapter Ia, we showed that increasing cholesterol levels were associated with faster rates of cognitive 
decline in ART-adherent HIV+ men between ages 50-65 years, an effect not observed in HIV- controls.  
Emerging data from cohort-studies suggest that HIV+ individuals are at increased risk for cardiovascular 
disease, arterial inflammation assessed by positron emission tomography with 18fluorine-2-deoxy-D-
glucose and high-risk atherosclerotic plaques compared to Framingham risk score-matched controls [57, 
58]. It is possible that statins therapy may attenuate the rate of midlife cognitive decline among HIV+ 
men through reduction in inflammation, atherosclerosis, cholesterol levels and/or yet unidentified 
mechanisms.   
 
In this section, we present preliminary data based on the methods described in chapter 1a to determine if 
cognitive decline is influenced by statin use in ART-adherent HIV+ men between ages 50-65 years, and 
whether statin therapy and total cholesterol levels interact to influence cognitive decline in HIV- infection.   
 
Statistical Methods  
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The association between statin use, HIV infection, and change in cognitive score was examined using 
mixed-effects models with interaction terms for statin use with time, HIV infection with time, and their 
joint interaction with time; statin use was analyzed as a dichotomous (statin vs. no statin), time-varying 
covariate.  Continuous variables included baseline age at study entry, CES-D score, and IQ score; CD4 cell 
count was examined as a time-varying covariate. Smoking and HIV infection were analyzed as binary 
covariates.  A backwards elimination procedure was used to identify significant longitudinal relationships 
among predictors (P <0.05 cut-off).  Random predictors were correlated intercepts and linear slopes of 
time. Analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC).   
 
Preliminary Results and Interpretation 
HIV+ men were more likely to report being on statin therapy than HIV- controls during a study visit (37% 
vs. 23% of total visits/group; data not shown).  A total of eight statin medications were reported; 
Simvastatin was used alone or in combination with Ezetimibe (Figure 1).  Lipitor was the most commonly 
used medication in both groups (61%); Pravastatin and Simvastatin were the second most common statin 
therapies among HIV+ and HIV- subjects, respectively.   
Statin Use, Total Cholesterol and Cognitive Decline 
Time-related terms reflecting the association between statin use, and cognitive decline are summarized in 
Table 1.  There was no significant relationship between statin use, and rate of decline in HIV+ men 
(p=0.40); the interaction in HIV- subjects was marginally significant (p=0.06).  Figure 2 illustrates these 
findings for a representative 50 year old man with or without HIV infection.  In a separate mixed-effects 
model that included terms for HIV infection, total cholesterol, statin use and their respective interactions 
with time, cholesterol level independently influenced the rate of cognitive decline in HIV+ men, 
corroborating results from chapter 1a (estimate= -0.00052U/yr; p= 0.02).  The association between statin 
use and cognitive decline in HIV+ men was marginally significant (p=0.05).  When the interaction 
between HIV infection, statin use, total cholesterol and time was tested, statin use substantially modified 
the association between total cholesterol and the annual rate of decline in HIV+ individuals (p=0.015; 
Figure 2 lower panel).  These findings suggest that in HIV+ men between ages 50-65 years, total 
cholesterol levels are independently associated with faster rates of cognitive decline, and statins 
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potentially influence cognitive decline through interactions with total cholesterol.  These are preliminary  
studies, and further work is needed to better understand the clinical cohort on statin therapy, the 
relationship between statin use and other lipid markers, and the influence of APOE E4 genotype on these 
respective associations.   
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Figure 1:  Statin Use in 279 ART-Adherent HIV+ and 516 HIV- Men Enrolled in the MACS 
Lasagna plots visualizing type of statin medication reported for each HIV+ (left) and HIV- (right) subject.  
Subjects’ person-visits are represented in a single row. The vertical order for the lasagna plots among 
HIV+ subjects is based on relative viral load suppression, with subjects demonstrating the greatest 
variability in HIV viral load at the bottom of the plot.  Grey values represent a study visit where additional 
data was available but statin use was not recorded.   
  
 
 
35 
 
Table 1:  Associated Effect of Statin Use and Total Cholesterol on the Annual Rate of Cognitive 
Decline  
Model 1:  Estimate SE P value 
HIV+ * Years in Study -0.0132 0.0071 0.303 
Statin Use * Years in Study 0.0073 0.0103 0.060 
Statin Use * HIV+ * Years in Study 0.0118 0.0140 0.400 
    Model 2:  
   HIV+ * Years in Study 0.0913 0.0298 0.322 
Statin Use * Years in Study 0.0286 0.0287 0.995 
Statin Use * HIV+ * Years in Study -0.0753 0.0374 0.050 
Total Cholesterol (10 mg/dl) * Years in Study  0.0014 0.0001 0.368 
Total Cholesterol (10 mg/dl) * HIV+ * Years in Study -0.0052 0.0001 0.018 
Total Cholesterol (10 mg/dl) * Statin Use * Years in Study -0.0010 0.0014 0.184 
Statin Use *Total Cholesterol (10 mg/dl) * HIV+ * Years in Study 0.0045 0.0002 0.015 
Model 2:  
   HIV+ * Years in Study 0.0913 0.0298 0.322 
Statin Use * Years in Study 0.0286 0.0287 0.995 
Statin Use * HIV+ * Years in Study -0.0753 0.0374 0.050 
Total Cholesterol (10 mg/dl) * Years in Study  0.0014 0.0001 0.368 
Total Cholesterol (10 mg/dl) * HIV+ * Years in Study -0.0052 0.0001 0.018 
Total Cholesterol (10 mg/dl) * Statin Use * Years in Study -0.0010 0.0014 0.184 
Statin Use *Total Cholesterol (10 mg/dl) * HIV+ * Years in Study 0.0045 0.0002 0.015 
Adjusted for age at study entry, Shipley WAIS IQ- Equivalent Score, CES-D at study entry,  
smoking status, and CD4 count. Total cholesterol was interpreted in 10 mg/dl increments. Model 1  
includes terms for statin use.  Model 2 includes terms for both statin use and total cholesterol. 
 Model 1: R2 for fixed effects= 0.23, P<0.001; Model 2: R2 for fixed effects= 0.25, P<0.001 
 The squared Pearson correlations of predicted values from fixed versus actual values of the dependent 
variable indicate the percent of variance accounted for by predictors.   A negative estimate indicates a 
faster rate (steeper slope) of cognitive decline. 
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Figure 2: The Association between Total Cholesterol Levels and the Annual Rate of Midlife 
Cognitive Decline is Modified by Statin Use in ART-adherent HIV+ Men 
Estimated slopes in neurocognitive scores according to time-varying statin use, and stratified by HIV 
infection are shown (top panel); the association between statin use, and cognitive decline in HIV+ men 
modified by total cholesterol is shown in the lower panel.  The slopes are estimated for a man with study 
entry age of 50, and cohort mean IQ score 108, baseline CES-D score 9, and CD4 count held at 800 
cells/ml.  The x-axis is time in study (years) centered at zero for the first visit after age 50, and y-axis is 
the change in cognitive performance from the baseline score. When investigated without adjustment for 
total cholesterol, there is no association between statin use, and the annual rate of cognitive decline 
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among HIV+ men (0.4).  In a separate mixed-effects model, higher total cholesterol was independently 
associated with a steeper slope of cognitive decline among HIV+ individuals (p= 0.02), and the rate of 
decline was substantially attenuated by statin use (p=0.015).  This suggests that cholesterol levels 
independently influences the rate of cognitive decline in HIV+ men between ages 50-65 years, and statin 
use modifies this association.   
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CHAPTER II: 
 
Predictors of Age-Related Cognitive Decline in Men with and without HIV-Infection 
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A. Objective:  
The relative contributions of the APOE ε4 genotype, systemic inflammation and CVD on cognitive 
decline among older ART-adherent HIV+ adults have not been established.  The proposed research 
leverages resources from our cohort of 789 ART-adherent HIV+ and HIV- adults from the longitudinal 
prospective Multicenter AIDS Cohort Study (MACS) in chapter 1 to determine the extent to which 
inflammatory markers, CVD risk factors, and APOE ε4 genotype account for cognitive decline among 
HIV+ adults on ART.  These aims utilize longitudinal cognitive modeling to examine the contribution of 
time-varying laboratory indices predictive of cognitive trajectories, determine the extent to which decline 
is attributable to these processes, and estimate change-points that signal the onset of cognitive 
impairment in HIV- and HIV+ subjects.  Together, these studies will help address whether common 
causes of dementia in the general population explain individual differences in cognitive decline among 
HIV-infected adults over age 50 years, and have potential translational implications for the development 
of therapeutic targets to prevent brain aging in HIV-infection and other neurodegenerative diseases. 
 
Aim 1: Examine the contribution of inflammatory markers, cardiovascular disease risk 
factors, and APOE ε4 genotype to the rate of cognitive decline in midlife HIV+ individuals.  
In the aim, we will test the hypothesis that circulating inflammatory markers (e.g. hsCRP, IL-6, TNF-α), 
CVD risk factors (hyperlipidemia, cigarette use, diabetes mellitus, and hypertension), and APOE ε4 
genotype (carrier vs. noncarrier) account for >50% of individual differences in the rates of cognitive 
decline among midlife ART-suppressed HIV+ adults. Using mixed-effects models, we will determine the 
influence of the above variables on the rate of cognitive decline on composite cognitive score, and in 
cognitive domains (i.e. verbal memory, processing speed, executive, motor) with directed comparisons 
between ART-adherent HIV+ subjects and matched HIV-controls ages 50-65.  First, to estimate the 
contribution of individual variables to the rate of decline, we will add in terms for the variable and its 
interaction with time in a series of models, as described [59].  The estimate for the variance in random 
time will capture how individual deviate from the mean slopes; thus, the time-by-variable term will 
account for a proportion of the total random slope variance, and the reduction in the random slope 
variance will reflect between-subject variation in cognitive decline.  In subsequent analyses, significant 
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variables will be considered simultaneously to determine the additive effect, and cumulative influence on 
between-subject variation in cognitive decline.   
    
Aim 2: Model change points to estimate when conversion to cognitive impairment occurs 
in ART-adherent HIV+ individuals. The goal of this aim is to divide cognitive paths into slow change 
and more rapid change components, and determines when significant variables identified in Aim 1 
influence the rate of decline in ART-suppressed HIV+ and HIV- adults over age 50 years.  We will fit a 
series of mixed-effects models that allow the rate of cognitive decline to change in the last n years before 
cognitive impairment (SD ≤ 1.0, two cognitive domains), and identify analyses with the best fit for the 
change point (time when rate of decline increases), as described [60].  We will then determine the effect of 
pathological indices in Aim 1 on the rate of decline at pre- and post-change point.  Analysis will be 
subsequently repeated using measures of specific cognitive functions in place of the composite cognitive 
score (impairment defined as SD ≤ 1.5, single cognitive domain). 
 
B. Research Approach: 
Subject populations: Subjects are drawn from the MACS, a multicenter prospective study conducted in 
Baltimore, Chicago, Pittsburgh, and Los Angeles of men who have sex with men [61-64].  Participants 
were evaluated at 6-month intervals for medical history (including cigarette use), medications including 
ART and structured neurocognitive testing. Blood/urine specimens were used to test for HIV antibody, T-
cell subsets, HIV viral load, HCV serology/plasma RNA, endocrine (fasting glucose, HOMA-IR, HgA1C), 
lipid (total cholesterol, LDL, HDL, triglycerides), inflammatory markers and APOE genotyping.  The 
Gabuzda lab created a local SQL database containing the entire public dataset streamlined for analysis. All 
subjects were enrolled with written informed consent and IRB approval and healthy plasma/CSF samples 
obtained from Bioreclamation with IRB approval from Dana-Farber Cancer Institute. 
 
Longitudinal neurocognitive analysis: MACS longitudinal neurocognitive variables were: Trail Making 
Test–Parts A and B[65]; Stroop Color/Word Interference Test ([66, 67]); Grooved Pegboard [68]; Symbol 
Digit Modalities Test[69]; California Computerized Assessment Package (CalCAP[70]); Rey Auditory 
Verbal Learning Test[71-73]. Scores from 15 of these tests will be converted to z-scores using the mean 
 
 
41 
 
and SD from HIV- men ages 45-49 years old, and z-scores will be averaged to yield a composite measure 
of cognition.  Z-scores are used in order to place scores from diverse cognitive tests on a common scale so 
that they could be combined with approximately equal weighting; further, the use of a composite score 
has the advantage of minimizing floor and ceiling effects, and is preferable for studies examining change 
in cognition over many years [59]. 
 
Subject selection and statistical/bioinformatic analysis: Cohorts include HIV-vs. HIV+ on suppressive 
ART ages 50-65 (see chapter 1). Exclusions include CNS related opportunistic infections, lymphoma, and 
heavy drug abuse.  Cohorts will be matched by baseline age, race, smoking, education and alcohol use 
using the R program MATCHIT. Aim1: Mixed-effects models will be used to determine rate of change in 
domain-specific and global cognitive function over time.  We will first begin with an unadjusted model 
with only the term for time; time is defined as the time (in years). The estimate for time (the slope) 
corresponds to the mean rate of decline in cognition, and the estimate for the variance in random slope 
captures how individuals deviate from the mean slopes [59]. We will add in terms for HIV-infection, other 
relevant HIV-disease characteristics, and for the variables of interest and their interactions with time in a 
series of models.  Aim2: Fixed change point analysis will be used to identify acceleration in the mean rate 
of decline in domain-specific and global cognitive outcome measures as described [60]. In brief, we will 
construct a series of mixed-effects models that allow the rate of cognitive decline to change in the last n 
years before cognitive impairment. We will test values of n ranging from 0.5 to 3 years, and the 
distribution of follow-up time in this cohort. Best fit will be defined as analysis with the highest log 
likelihood. 
 
Power calculations:  We identified a cohort of 789 HIV- and ART-adherent HIV+ from the MACS.  A 
power calculation estimates we require minimum sample size of 90 subjects in each group to detect a 
standardized mean difference of 0.3 with an 85% power using a two-sided 0.05 Wilcoxon test.  This 
supports the proposed dataset is powered to detect differences without inclusion of further subjects.  
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Conclusions  
Aging is characterized by progressive cognitive decline, and the prevention of cognitive impairment is a 
major public health challenge in the 21st century [12, 59, 60].  Superimposed effects of HIV-associated 
inflammation and oxidative injury may increase the rate of cognitive decline among a subset of ART-
suppressed HIV+ individuals over age 50 years.  Cognitive decline in old age regardless of HIV serostatus 
is a complex phenomenon, and there is considerable heterogeneity in cognitive trajectories; thus, 
longitudinal modeling of cognitive performance at a group and subject-specific level is required to 
understand how relevant risk factors affect HIV-infected adults, and compare rates of decline to HIV- 
populations. 
The presented work shows how mixed-effects analysis can be employed to estimate the rate of cognitive 
decline among ART-adherent HIV+ individuals and HIV- controls, and how known risk factors for 
cognitive decline in the general population (i.e. dyslipidemia and APOE ε4 genotype) differentially modify 
the rate of decline among HIV+ individuals over age 50 years.     The second part of this thesis describes 
how we will test the influence of pathological variables and genetic markers (systemic inflammation, CVD 
risk factors, and APOE ε4 genotype) on cognitive decline, and determine the extent to which these factors 
account for differences in cognitive trajectories.  Modeling longitudinal trajectories of midlife cognitive 
performance in HIV-infection, and determining the explained versus unexplained variance has important 
implications as this knowledge can help set HIV-related research priorities related to dementia prevention 
in old age.  Additional value of these studies would be in designing clinical trials for people living with 
HIV infection.  To date, clinical trials for HIV-associated neurocognitive disorders have largely been 
unsuccessful [74].  A potential reason is due in cognitive heterogeneity; some individuals decline rapidly, 
others have slower decline, and others remain stable or improve as a result of practice[59].  By identifying 
the relevant pathological variables, and estimating the contribution of these variables to rate of decline, 
we may better predict who will likely respond to treatments.   
Published guidelines in Alzheimer’s disease suggest that the best time to intervene is most likely prior to 
the onset of clinical symptoms, and this strategy likely will translate to HIV-related cognitive disorders 
[75].  Thus, early identification of relevant clinical and imaging biomarkers predictive of cognitive decline 
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in virally suppressed HIV+ populations is required.   Given HIV-infected adults older than 55 years 
comprise one of the fastest growing age groups in the HIV+ population, this thesis highlights the value of  
longitudinal modeling to uncover determinants contributing to cognitive decline in HIV+ populations 
[76].  
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